Assessing Keymed Biosciences (SEHK:2162) Valuation After CMG901 Phase III Milestone With AstraZeneca

Simply Wall St.03-17

Keymed Biosciences (SEHK:2162) is back in focus after partner AstraZeneca began a Phase III trial of CMG901 in advanced gastric and related cancers, triggering a US$45 million milestone payment to the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620963044?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-17 01:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620963044","market":"us","top_or_hot":-1,"title":"Assessing Keymed Biosciences (SEHK:2162) Valuation After CMG901 Phase III Milestone With AstraZeneca","media":"Simply Wall St.","content":"<div>\n<p>Keymed Biosciences (SEHK:2162) is back in focus after partner AstraZeneca began a Phase III trial of CMG901 in advanced gastric and related cancers, triggering a US$45 million milestone payment to the...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/assessing-keymed-biosciences-sehk2162-valuation-after-cmg901\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Keymed Biosciences (SEHK:2162) Valuation After CMG901 Phase III Milestone With AstraZeneca</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Keymed Biosciences (SEHK:2162) Valuation After CMG901 Phase III Milestone With AstraZeneca\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-17 01:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/assessing-keymed-biosciences-sehk2162-valuation-after-cmg901><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Keymed Biosciences (SEHK:2162) is back in focus after partner AstraZeneca began a Phase III trial of CMG901 in advanced gastric and related cancers, triggering a US$45 million milestone payment to the...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/assessing-keymed-biosciences-sehk2162-valuation-after-cmg901\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/assessing-keymed-biosciences-sehk2162-valuation-after-cmg901","article_id":"2620963044","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/assessing-keymed-biosciences-sehk2162-valuation-after-cmg901","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620963044","pubTimestamp":1773681497,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Keymed Biosciences (SEHK:2162) is back in focus after partner AstraZeneca began a Phase III trial of CMG901 in advanced gastric and related cancers, triggering a US$45 million milestone payment to the group.\nSee our latest analysis for Keymed Biosciences.\nThe CMG901 Phase III update comes after a strong 1 year total shareholder return of 50.97%. Shorter term share price momentum is steadier, with a 7 day share price return of 6.36% around the HK$54.35 level.\nIf you are looking for other...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK4134":"信息科技咨询与其它服务","02162":"康诺亚-B","BK1583":"高瓴概念","III":"信息服务","BK1161":"生物科技","BK1587":"次新股","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"与阿斯利康合作完成CMG901 III期里程碑后评估康康生物科技(SEHK：2162)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"02162":0.9,"III":1.5},"content_text":"Keymed Biosciences (SEHK:2162) is back in focus after partner AstraZeneca began a Phase III trial of CMG901 in advanced gastric and related cancers, triggering a US$45 million milestone payment to the group. See our latest analysis for Keymed Biosciences. The CMG901 Phase III update comes after a strong 1 year total shareholder return of 50.97%. Shorter term share price momentum is steadier, with a 7 day share price return of 6.36% around the HK$54.35 level. If you are looking for other healthcare names linked to the AI theme in drug discovery and diagnostics, this is a good moment to scan 123 healthcare AI stocks With the shares sitting around HK$54.35, some valuation models flag a sizeable gap versus estimated worth. However, the company is still loss making, so readers need to ask whether this is a genuine opportunity or if markets already price in future growth. AdvertisementPreferred Price to Sales of 16.2x: Is it justified? On a P/S of 16.2x, Keymed Biosciences trades at a richer level than much of the Hong Kong biotech space, despite still reporting losses. The P/S ratio compares the company’s market value to its revenue, which can be useful for early stage or unprofitable biotechs where earnings are not yet positive. For Keymed, the current 16.2x P/S is described as good value against a peer average of 17x. It also stands above both the Hong Kong biotechs industry average of 13.4x and an estimated fair P/S of 13x. That indicates the current market price is higher than the level that regression based fair value work points to and highlights a gap that could close if sentiment or revenue expectations adjust. Explore the SWS fair ratio for Keymed Biosciences Result: Price to Sales of 16.2x (OVERVALUED) However, you still have to weigh clinical trial setbacks or delays, as well as the company’s current CN¥257.339 million loss, as potential pressure points on sentiment. Find out about the key risks to this Keymed Biosciences narrative. Another View: DCF Suggests Room Above HK$54.35 While the 16.2x P/S ratio screens as expensive versus the Hong Kong biotechs industry fair ratio of 13x, the SWS DCF model points the other way. On that approach, Keymed Biosciences at HK$54.35 trades around 59% below an estimated HK$132.43 per share fair value. It is up to you to decide which signal you consider more important. Look into how the SWS DCF model arrives at its fair value. 2162 Discounted Cash Flow as at Mar 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Keymed Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 227 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With mixed signals from P/S and DCF in mind, it is worth checking the details for yourself and acting while the facts are fresh. You can start with a closer look at the 4 key rewards and 1 important warning sign. Looking for more investment ideas? If you stop with just one company, you might miss better fits for your portfolio, so use the tools available and compare a few strong options side by side.  Target resilient returns by checking out 302 resilient stocks with low risk scores that may help smooth out the bumpier parts of your portfolio. Hunt for quality at a sensible price by scanning 227 high quality undervalued stocks that combine solid fundamentals with room for potential upside. Grow your passive income stream by reviewing 464 dividend fortresses that focus on higher yielding payouts.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Keymed Biosciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620963044","isCrawlerRequest":true}